|
市場調査レポート
商品コード
1353109
大腸がん検診の世界市場規模、シェア、産業動向分析レポート:タイプ別、エンドユーザー別、地域別展望と予測、2023年~2030年Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based), By End-user, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
大腸がん検診の世界市場規模、シェア、産業動向分析レポート:タイプ別、エンドユーザー別、地域別展望と予測、2023年~2030年 |
出版日: 2023年08月31日
発行: KBV Research
ページ情報: 英文 263 Pages
納期: 即納可能
![]() |
大腸がん検診市場規模は2030年までに222億米ドルに達し、予測期間中にCAGR 4.8%の市場成長率で上昇すると予測されています。
KBV Cardinalのマトリックスに示された分析によると、シーメンス・ヘルティニアスAGが市場の先駆者です。2021年4月、シーメンスはバリアンメディカルシステムズを買収し、シーメンス・ヘルスニイヤーズの競争力と独立性を強化しました。富士フイルムホールディングス株式会社、オリンパス株式会社、BioMerieux S.A.などの企業が市場における主要なイノベーターです。
COVID-19影響分析
COVID-19の影響により、パンデミックの間、市場の成長は鈍化しました。パンデミック時代の封鎖制限と大腸がん検診の中止がこれをもたらしました。人と人との接触を減らし、COVID-19に曝露した人々のために病院や医療資源を節約するため、大腸内視鏡によるスクリーニングは2020年に多くの国で完全に中止されました。パンデミック期間中、市場は売上高で見ると成長が鈍化しました。パンデミック期間中、政府プログラムによる検査対象者数が減少しました。
市場成長要因
大腸がんリスクの増大
世界の大腸がん罹患率の大幅な上昇は、市場拡大に好影響を与える重要な要因の1つです。罹患率は先進国で最も高く、中低所得国では不健康なライフスタイルの選択と人口の爆発的な高齢化のために上昇しています。また、米国がん協会によると、米国では2020年に直腸がんが43,340例、結腸がんが104,610例新たに確認されます。CRCの罹患率の上昇と同疾患の死亡率の上昇により、CRC検出の需要が高まっており、これが次年度以降の市場拡大の原動力となる可能性が高いです。
政府のがん検診政策
いくつかの国の政府は、世界規模で大腸がんの発生率を減らすためにスクリーニング政策を強化しています。数カ国の政府は、CRCの増加する負担を軽減するため、罹患リスクのある個人を対象とした定期的な検診プログラムなど、さまざまな取り組みを実施しています。2019年に国立医学図書館が発表した研究によると、韓国では国立がん検診プログラムが50歳以上のすべての成人にCRC検診を無料または低料金で提供しています。高齢者人口の増加や政府の取り組みにより、各種検査の利用が増加することが予想され、市場全体の拡大に弾みがつくと思われます。
市場抑制要因
大腸内視鏡検査の悪影響が検査導入の減少につながる可能性
高度で効率的なスクリーニング検査の必要性が高まっているにもかかわらず、スクリーニング検査機器の導入はその固有の制限によって妨げられる可能性があります。例えば、大腸内視鏡検査は最も陽性率が高く、精度の高い検査です。しかし、患者は出血や感染など、大腸内視鏡検査の過程でいくつかの副作用を経験する可能性があります。予測期間中、大腸がんスクリーニング技術に関連するこうした制限や好ましくない影響は、市場の拡大を抑制すると予想されます。
タイプ別展望
タイプ別では、便検査、大腸内視鏡検査、その他に区分されます。便ベースのセグメントは2022年の市場でかなりの収益シェアを占めています。便に基づく検査による大腸がんおよび前がん病変の診断は有望な結果を示しており、早期発見のための有用なツールとなっています。革新的な便ベースの検査は、便サンプルを分析して大腸がんに関連する特定のDNAマーカーを見つける。大腸がん検診のための政府プログラムの増加と便ベースの検査の効率性がこのセグメントの成長に寄与しています。
便ベースタイプの展望
便ベースのセグメントでは、市場はさらに便免疫化学検査(FIT)、便潜血検査(FOBT)、便DNA検査に分けられます。便免疫化学検査(FIT)セグメントは、2022年の市場で最大の収益シェアを示しました。FIT(便免疫化学検査)は、便中の血液を同定するために使用される非侵襲的診断手順です。FITは、便サンプル中の血液を検出することで、前がん病変や早期大腸がんを検出する診断ツールとして広く利用されています。FITの開発は、感度、特異度、患者への優しさを高めることに重点を置いています。
エンドユーザーの展望
エンドユーザーに基づき、市場は病院・診療所、臨床検査室、画像診断センター、その他に二分されます。2022年には、病院・診療所セグメントが最大収益シェアで市場を独占しました。このセグメントの成長は、大腸がんの有病率の上昇と、世界的に病院で実施されるスクリーニング検査の技術進歩に起因します。CRCスクリーニングの需要は、相当数の病院を含む要素により、病院や診療所で拡大しています。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、アジア太平洋地域が市場で大きな収益シェアを獲得しました。同地域市場の拡大は、アジア諸国におけるヘルスケア施設の市場開拓とアップグレード、同地域諸国におけるCRC罹患率の上昇、より良い治療結果に対する個人の意識の高まりが原動力となっています。また、同地域の主要国における大腸がんの罹患率の上昇や、大腸疾患が主要な死亡原因となっていることも、同地域の市場成長を促進すると予想されます。
The Global Colorectal Cancer Screening Market size is expected to reach $22.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.
In United States, approximately nine out of ten people with colorectal cancer who are diagnosed early and treated appropriately are still alive five years later. Hence, the North America region would capture approximately 2/5th of the market by 2030. Due to several factors, including an aging population, an increase in cancer cases, high healthcare spending, and a modern healthcare infrastructure. The market is also expanding due to rising government initiatives to create awareness of the disease and the accessibility of screening tests like FIT and FOBT.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In April, 2022, BioMerieux S.A. acquired Specific Diagnostics to enhances bioMerieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio. In December, 2022, Olympus Corporation took over Odin Vision to reinforce Olympus' strategy for delivering digital patient care.
Based on the Analysis presented in the KBV Cardinal matrix; Siemens Healthineers AG is the forerunner in the Market. April, 2021, Siemens took over Varian Medical Systems to strengthen the competitiveness & independence of Siemens Healthineers. Companies such as Fujifilm Holdings Corporation, Olympus Corporation, BioMerieux S.A. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The COVID-19 effect caused the market growth to slow down during the pandemic. Pandemic-era lockdown limitations and a suspension of colorectal cancer screening brought this on. To decrease person-to-person contact and conserve hospital and medical resources for those exposed to COVID-19, screening through colonoscopies was completely discontinued in many countries in 2020. The market slowed in growth during the pandemic period when measured by revenue. During the pandemic, there was a decrease in the number of people being examined through government programs.
Market Growth Factors
Growing Risk of Colorectal Cancer
The substantial rise in global colorectal cancer incidence is one of the key factors that favorably influence the market's expansion. The incidence is highest in developed nations, rising in middle- and low-income nations because of unhealthy lifestyle choices and an aging population explosion. Additionally, according to the American Cancer Society, 43,340 new instances of rectal cancer and 104,610 new cases of colon cancer were identified in the United States in 2020, respectively. The demand for CRC detection has increased due to the rising incidence of CRC and the disease's rising death rate, which will likely drive the expansion of the market in the following years.
Government Cancer Screening Policies
Governments in several nations have strengthened screening policies to reduce the incidence of colorectal cancer on a global scale. Governments in several nations have implemented various initiatives, such as regular screening programs for individuals at risk of contracting the disease, to reduce the growing burden of CRC. In Korea, the National Cancer Screening Program offers CRC screening to all adults over 50 at no or at a low cost, according to a study released by the National Library of Medicine in 2019. The usage of various tests is anticipated to increase due to the growing elderly population and government initiatives, which will fuel market expansion overall.
Market Restraining Factors
Negative Effects of Colonoscopies May Lead to Decreased Adoption of Testing
Despite the critical and growing need for advanced and efficient screening procedures, adopting screening devices may be hampered by their inherent limitations. A colonoscopy, for instance, has the highest incidence of positive results and is a highly accurate test. However, the patient may experience several negative side effects from the colonoscopy process, including bleeding and infection. During the forecast period, these restrictions and unfavorable effects related to colorectal cancer screening techniques are anticipated to restrain market expansion.
Type Outlook
By type, the market is segmented into stool-based, colonoscopy, and others. The stool-based segment covered a considerable revenue share in the market in 2022. The diagnosis of colorectal cancer and precancerous lesions using stool-based tests has shown encouraging results, making it a useful tool for early detection. The revolutionary stool-based tests analyze stool samples to find specific DNA markers related to colorectal cancer. Increased government programs for colorectal cancer screening and the efficiency of stool-based tests have contributed to the segment's growth.
Stool-based type Outlook
Under the stool-based segment, the market is further divided into fecal immunochemical test (FIT), fecal occult blood test (FOBT), and stool-DNA test. The fecal immunochemical test (FIT) segment witnessed the largest revenue share in the market in 2022. The FIT, or fecal immunochemical test, is a non-invasive diagnostic procedure used to identify blood in stool. FITs are extensively utilized diagnostic tools for detecting precancerous lesions or early-stage colorectal cancer by detecting blood in stool samples. The development of FITs has focused on enhancing their sensitivity, specificity, and patient friendliness.
End-user Outlook
Based on end-user, the market is bifurcated into hospital & clinics, clinical laboratories, diagnostic imaging centers, and others. In 2022, the hospitals and clinics segment dominated the market with maximum revenue share. The growth of the segment is attributable to the rise in the prevalence of colorectal cancer and technological advancements in screening tests conducted in hospitals globally. The demand for CRC screening is expanding in hospitals and clinics due to elements including a sizable number of hospitals.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. The expansion of the regional market is driven by the development and upgrading of healthcare facilities in Asian nations, rising CRC incidence in the region's nations, and rising individual consciousness of better treatment outcomes. It is expected that the rising incidence of colorectal cancer in the region's key countries and the status of colorectal diseases as the primary cause of mortality will also drive market growth in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG)
Strategies deployed in Colorectal Cancer Screening Market
Jul-2023: BioMerieux S.A. signed a partnership with Oxford Nanopore, a medical technology company, to provide nanopore sequencing solutions within the infectious disease diagnostics market. The partnership provides BioMerieux with opportunities for exploring new technologies for improved patient care.
Dec-2022: Olympus Corporation took over Odin Vision, an endoscopy solutions provider. The acquisition reinforces Olympus' strategy for delivering digital patient care.
Apr-2022: BioMerieux S.A. acquired Specific Diagnostics, an antimicrobial susceptibility test (AST) specialist. The acquisition enhances bioMerieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio.
May-2021: Fujifilm Holdings Corporation signed a partnership with Helio Health, an AI-powered healthcare solutions provider, to develop solutions for early detection of liver cancer. The partnership would provide clinicians around the world with market-leading diagnostic and surveillance technologies.
Apr-2021: Siemens took over Varian Medical Systems, a U.S. company active in the region of cancer research & therapy. This acquisition would allow Siemens to strengthen the competitiveness & independence of Siemens Healthineers. The acquisition further focused on creating a world-leading company in cancer therapy.
Jan-2021: Fujifilm Holdings Corporation expanded its geographical footprint by opening a new centre named "NURA" in Bangalore, India. The centre would serve as a medical screening service business for the company.
Market Segments covered in the Report:
By Type
By End-user
By Geography
Companies Profiled
Unique Offerings from KBV Research